8-K current report · filed Nov 9, 2026

Neurogene Inc. (NGNE) 8-K Current Report: November 9, 2026

Item 2.02Item EX-99.2Item EX-99.1NGNE overview

Short answer

Neurogene Inc. (NGNE) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for quarter ended September 30, 2026.

Neurogene Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Updated corporate presentation highlights current corporate and investor messaging
  • Detailed results and business updates available in Exhibits 99.1 and 99.2

Item EX-99.1 · Exhibit EX-99.1

  • Embolden topline data expected 2H 2027, with 25 participants in primary efficacy analysis and a 9-of-25 success threshold
  • NGN-401 1E15 vg dose generally well-tolerated across 35 participants as of November 8, 2026
  • PPQ runs remain on track for year-end 2026, supporting planned BLA submission and commercialization readiness
  • Cash, cash equivalents and short-term investments totaled $359.7 million, funding operations into Q1 2029
  • Q3 R&D expense rose to $23.5 million from $17.2 million, while net loss increased to $29.0 million from $21.0 million

Item EX-99.2 · Exhibit EX-99.2

  • Embolden registrational trial fully dosed, N=25, exceeding target enrollment and supporting a potential broad age label for patients ≥3 years
  • Topline Embolden data expected 2H 2027, the key clinical catalyst for NGN-401’s potential approval
  • Phase 1/2 results: 100% of participants gained ≥1 milestone, 80% met the composite responder definition at 12 months
  • Durable efficacy signal: 4.7 average milestones gained per participant at ≥12 months, with no milestone losses through 30 months
  • BLA-enabling PPQ runs expected by year-end 2026, advancing manufacturing readiness ahead of a planned regulatory submission

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Neurogene Inc. 8-K filings

Get the next NGNE 8-K as it lands

Follow NGNE for push alerts, or ask the research agent what this filing means.